NOTE! This site uses cookies

By continuing to browse the site you are agreeing to our use of cookies. For more detalis, see Read more

Accept

What are you looking for?


Grífols buys 21.3% of biotech company TiGenix for €12 million

Catalan pharmaceutical company Grífols has purchased 21.3% of Belgian biotech company TiGenix for €12 million through the subscription of a capital increase. TiGenix is a leading company in the field of cell therapy. The agreement settled on the appointment of two Grífols Members on TiGenix’s Board and a preferential right to negotiate the development and commercialization of all TiGenix products, with the only exception of advanced-medicinal product ChondroCelect. Earlier this month, Grífols had already strengthened its therapeutic arsenal by buying part of the Diagnostics unit of Swiss multinational Novartis for $1,675 million.

SHARE

21 November 2013 01:04 PM

by

ACN

Barcelona (ACN).- Catalan pharmaceutical company Grífols has purchased 21.3% of Belgian biotech company TiGenix for €12 million through the subscription of a capital increase with the exclusion of subscription rights for TiGenix N.V. TiGenix is a leading company in the field of cell therapy, listed at NYSE Euronext Brussels. It has its headquarters in Louvain (Leuven in Flemish), along with centres in Madrid and Sittard-Gelcen (The Netherlands). The agreement settled on the appointment of two Grífols Members on TiGenix’s Board and a preferential right to negotiate the development and commercialization of all TiGenix owned product, with the only exception of advanced-medicinal product ChondroCelect. Earlier this month, Grífols had already strengthened its therapeutic arsenal by buying part of the Diagnostics unit of Swiss multinational Novartis for $1,675 million. The Catalan company is a world leader in blood-derivate pharmaceutical products, with a significant presence in the United States and South-East Asia.


ChondroCelect, which is excluded from Grífols’ agreement, is an advanced-medicinal therapies product. TiGenix , 100% shareholder of TiGenix SA, obtained the first approval in Europe for this product. TiGenix S.A. - formerly known as Cellerix S.A. - is a company dedicated to researching and developing stem cells derived from adipose tissue.

The €12 million investment has been made through Gri-Cel S.A. - 100% owned by Grífols. Gri-Cel’s main objective is to manage and invest in companies dedicated to advanced-medicinal therapies and personalised medicine.

SHARE

  • A Grífols' lab in Parets del Vallès, Greater Barcelona (by ACN)

  • A Grífols' lab in Parets del Vallès, Greater Barcelona (by ACN)